European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 2 , Pages 187-192 , August 2008

Effect of raloxifene on the vaginal epithelium of postmenopausal women

  • Armando Delmanto

      Affiliations

    • Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University—UNESP, Rubiao Junior, Botucatu, Sao Paulo 18618-970, Brazil
    • ,
  • Jorge Nahas-Neto

      Affiliations

    • Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University—UNESP, Rubiao Junior, Botucatu, Sao Paulo 18618-970, Brazil
    • ,
  • Eliana A.P. Nahas

      Affiliations

    • Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University—UNESP, Rubiao Junior, Botucatu, Sao Paulo 18618-970, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55 14 38116227; fax: +55 14 38821933.
    • ,
  • Maria Luiza C.S. de Oliveira

      Affiliations

    • Department of Pathology, Botucatu Medical School, Sao Paulo State University—UNESP, Sao Paulo, Brazil
    • ,
  • Cesar E. Fernandes

      Affiliations

    • Department of Gynecology and Obstetrics, ABC Medical School, Sao Paulo, Brazil
    • ,
  • Paulo Traiman

      Affiliations

    • Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University—UNESP, Rubiao Junior, Botucatu, Sao Paulo 18618-970, Brazil

Received 14 September 2007 ,Revised 21 December 2007 ,Accepted 21 January 2008.

References 

  1. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52:S46–S52
  2. Society of Obstetricians and Gynaecologists of Canada (SOGC). The detection and management of vaginal atrophy. Int J Gynaecol Obstet 2005;88:222–8.
  3. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms α and β messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol. 2001;185:1325–1331
  4. Carley ME, Rickard DJ, Gebhart JB, Webb MJ, Podratz KC, Spelsberg TC. Distribution of estrogen receptors alfa and beta mRNA in mouse urogenital tissues and their expression after oophorectomy and estrogen replacement. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:141–145
  5. Nothnagle M, Taylor JS. Vaginal estrogen preparations for relief of atrophic vaginitis. Cochrane for clinicians: putting evidence into practice. AFP 2004;69:1–4. http://www.cochrane.org/cochrane/revabstr/AB001500.htm.
  6. Heinemann C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can J Microbiol. 2005;51:777–781
  7. NAMS. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Society. Menopause 2007;14:355–69.
  8. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9:1980–1989
  9. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151–196
  10. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88:123–125
  11. Davis AM, Ellersieck MR, Grimm KM, Rosenfeld CS. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Mol Reprod Res. 2006;73:1034–1044
  12. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer. 2001;65:125–134
  13. Martino S, Cauley JA, Barrett-Connor E, et al. For the CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–1761
  14. Vogel VG, Constantino JP, Wiekerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–2741
  15. Koss LG. Cytologic evaluation of menstrual disorders and hormonal abnormalities. In:  Koss LG,  Melamed MR editor. Koss's diagnostic cytology and its histophologic bases. Philadelphia: Lippincott Wlilliams & Wilkins; 2005;p. 227–240
  16. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators; a systematic review. Climacteric. 2005;8:214–220
  17. WHO. Diet, nutrition and the prevention of chronic diseases. World Health Organization. Geneva: WHO/FAO (Reposts of WHO/FAO. Expert consultation on diet, nutrition and prevention of chronic diseases); 2002.
  18. Frost JK, Novak EL, Woodrugg JD. Gynecology and obstetrics pathology. Philadelphia: Saunders; 1962;p. 602
  19. Meisels A. The maturation value. Acta Cytol. 1967;11:249–253
  20. Checa MA, Garrido A, Prat M, Conangla M, Rueda C, Carreras R. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of longstanding postmenopausal hormone therapy in osteoporotic women: a randomized masked-evaluator, one-year, prospective study. Maturitas. 2005;52:70–77
  21. Gompel A. Molecular action of estrogens and anti-estrogens. Maturitas. 2006;54:313–314
  22. Goldstein I, Traish A, Kim N, Munarriz R. The role of steroid hormones in female sexual function and dysfunction. Clin Obstet Gynecol. 2004;47:471–484
  23. Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifene and estrogen. Am J Obstet Gynecol. 2003;189:81–88
  24. Komi J, Lankinen KS, Härkönen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005;12:202–209
  25. Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E. The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil Steril. 2007;88:530–532
  26. Hascalik S, Celik O, Tamser M, Mizrak B. Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats. Gynecol Obstet Invest. 2005;60:186–191
  27. Wang XN, Simmons HA, Salato CT, Cosgrove PG, Thompson DD. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor β and androgen receptor in rats. Menopause. 2006;13:609–620
  28. Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric. 2003;6:248–256
  29. Parsons A, Merritt D, Rosen A, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or non-hormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol. 2003;101:346–352
  30. Malacara JM, Perez-Luque EL, Martinez-Garza S, Sanches-Marin FJ. The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women. Maturitas. 2004;15(49):163–169

PII: S0301-2115(08)00100-0

doi: 10.1016/j.ejogrb.2008.01.017

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 2 , Pages 187-192 , August 2008

Article Tools